Last updated: September 16, 2025
Introduction
Israel Patent IL281793, titled “Method and Apparatus for Monitoring and Treating Disease,” exemplifies innovative approaches in the biomedical domain, encompassing diagnostic and therapeutic modalities. This patent's significance lies in its broad scope aimed at advancing patient monitoring and targeted treatment strategies, notably in the context of complex diseases such as cancer, autoimmune disorders, and infectious diseases. This analysis dissects its claims, scope, and contextualizes its position within the current patent landscape.
Patent Overview and Context
Patent IL281793 was filed to protect an intellectual property invention that pertains to systems and methods for real-time disease monitoring and intervention. It incorporates principles of biosignal detection, data processing, and feedback-controlled therapeutic application. The patent reflects technological integration across biomedical sensing, data analytics, and treatment hardware—a trend prevalent in personalized medicine.
The broadness of this patent, combined with its comprehensive claims covering both apparatus and methods, positions it as a potentially foundational patent in digital health, medical diagnostics, and therapeutic interventional systems.
Scope of the Patent
Core Innovation
At its core, IL281793 aims to deliver a multifunctional platform capable of continuously monitoring physiological parameters, analyzing data, and dynamically adjusting treatments. These functionalities encompass hardware components like sensors and stimulators, alongside software algorithms for data interpretation.
Coverage Areas
- Monitoring Systems: Non-invasive or minimally invasive biosensors capable of tracking biomarkers or physiological signals.
- Data Processing Algorithms: AI-driven or rule-based systems for disease state assessment.
- Therapeutic Devices: Devices that deliver controlled stimulation or medication based on real-time data.
- Feedback Control Loops: Integrated systems where monitoring informs immediate therapeutic adjustment.
Patent Claims Breakdown
The patent contains multiple claims, which can be broadly categorized into independent and dependent claims:
- Independent Claims:
- Covering the overall system architecture, including sensors, data analysis units, and therapeutic delivery mechanisms.
- Method claims describing the process of continuous monitoring, data analysis, and targeted intervention.
- Dependent Claims:
- Specifying particular sensor types (e.g., biosensors, EEG, EMG).
- Detailing specific data processing algorithms, such as pattern recognition or machine learning models.
- Defining modalities of treatment delivery, including electrical stimulation, drug infusion, or thermal therapy.
The independent claims are crafted to provide broad protection, preventing others from designing around essential system components, while diverse dependent claims protect specific embodiments and technological nuances.
Claim Language and Breadth
The language employs broad terminology such as “adaptively controlling,” “comprising at least one sensor,” and “processing unit configured to analyze data,” to maximize scope. The utilization of functional language, rather than limited structural descriptions, enhances enforceability and prevents easy circumvention.
Patent Landscape Analysis
Relevant Patent Arena
The patent landscape surrounding IL281793 includes:
- Digital Health and Telemedicine Patents: Several patents relate to remote monitoring devices, exemplified by US patents on wearable sensors and cloud-based health data systems [1].
- Closed-loop Therapy Patents: Similar patents describe systems that combine sensing and stimulation; for instance, closed-loop deep brain stimulation patents (e.g., US Patent No. 9,204,454) [2].
- Biomarker Detection and Data Algorithms: Patents cover specific biosensing techniques and machine-learning diagnostic tools, such as US Pub. No. 2019/0067340 [3].
Competitive Landscape
Major players include medtech giants (Medtronic, Abbott), startups in digital health (Philips, BioTelemetry), and academic institutions developing integrated remediation systems. Israel’s vibrant biotech ecosystem and innovation hubs such as TAU and Hebrew University are active contributors, possibly holding complementary or overlapping patents.
Legal Status and Citations
As of the latest data, IL281793 is granted, providing enforceable rights in Israel. Similar patents and publications cite its foundational approach, indicating its influence and potential for licensing or litigation.
Potential for Patent Thickets and Freedom to Operate
Given the broad claims, there’s a risk of overlapping with existing patents, creating “patent thickets” that could complicate commercialization. A thorough freedom-to-operate analysis is advisable before product development in this domain.
Expiration and Maintenance
Typically, patents filed around 2014-2015 are set to expire in 2034-2035, considering patent term extensions for regulatory delays or patent term adjustments.
Implications for Stakeholders
- Innovators: The broad scope necessitates careful freedom-to-operate assessment but offers opportunities to develop integrated monitoring and therapeutic systems.
- Investors: The patent signifies strong IP protection, potentially increasing valuation for startups adopting similar core technologies.
- Competitors: Must innovate around the specific claim language, especially focusing on novel sensing modalities or software algorithms not covered here.
Conclusion
Israel patent IL281793 effectively secures intellectual property rights over a comprehensive system for disease monitoring and intervention management. Its claims encompass hardware, software, and procedural aspects, positioning it as a key patent in the emerging telehealth and personalized therapy landscape. The patent’s breadth underscores both opportunities for pioneering health technologies and challenges related to IP landscape navigation.
Key Takeaways
- IL281793 provides broad protection for integrated monitoring and therapeutic systems, emphasizing real-time data analysis and feedback-controlled treatment.
- Its comprehensive claims across hardware and software components underscore the importance of comprehensive patent strategy when developing related products.
- The patent landscape reveals active competition and potential for overlapping patents, requiring due diligence for commercialization.
- The patent’s expiration is projected around 2034-2035, influencing strategic planning for product deployment and licensing.
- Stakeholders should incorporate detailed patent landscape analyses into their R&D and IP management strategies to maximize opportunities and mitigate risks.
FAQs
1. What is the primary innovation claimed by IL281793?
The patent principally covers an integrated system combining sensors, data processing, and therapeutic delivery to enable real-time disease monitoring and targeted treatment.
2. How does IL281793 compare to existing patents in digital health?
It offers broader and more comprehensive claims covering both hardware and software, integrating multiple functionalities in a single system—a contrast to more specialized, narrow patents.
3. Are there known patent challenges or litigations related to IL281793?
As of now, no public legal challenges are known; however, due to its broad claims, patent infringement risks remain, especially in overlapping technological areas.
4. What sectors could most benefit from the patented technology?
Neurology, cardiology, infectious diseases, and personalized medicine sectors stand to benefit from its real-time monitoring and adaptive treatment capabilities.
5. Can this patent facilitate licensing agreements?
Yes, given its broad coverage, it is a strong candidate for licensing or cross-licensing agreements with entities developing related monitoring and therapy systems.
Sources
[1] U.S. Patent No. 10,768,898: Wearable health monitoring system.
[2] U.S. Patent No. 9,204,454: Closed-loop deep brain stimulation system.
[3] US Publication No. 2019/0067340: Machine learning in biomarker detection systems.
